Nippon India Pharma Fund - Growth has delivered CAGR and average rolling returns as follows :
1 Year | 3 Year | 5 Year | 9 Year | |
CAGR(%) | 51.12 | 15.73 | 22.73 | 14.06 |
Average Rolling Returns(%) | 18.85 | 17.55 | 15.98 | 18.56 |
The Current NAV of Nippon India Pharma Fund - Growth is ₹428.69.
You should look for a fund with better more consistent performance track record. Funds returns are more likely to be different than its benchmark NIFTY 500 returns, as Funds portfolio is significantly different.
Nippon India Pharma Fund - Growth fund’s expense ratio is 1.82%
The process for redemption is
The AUM of Nippon India Pharma Fund - Growth is currently ₹7,133 Crores.
The Top three stocks are Sun Pharma Inds., Lupin and Cipla and account for 28% of its portfolio. Top 5 and 10 stocks of fund account for 39% and 58% of fund’s portfolio respectively.
Top three sectors of Nippon India Pharma Fund - Growth fund are Healthcare, Miscellaneous and accounting for 100% of the total portfolio.
Funds Portfolio Quality is Very Good. It has a large proportion of Green Stocks.Since this is a Equity - Sectoral Fund - Pharma & Health Care it is comparatively safer to invest in this fund. However, since it has not consistently outperformed its benchmark index on an average 3-year rolling returns basis it is not the most suitable fund for SIP.
The category of Nippon India Pharma Fund - Growth Fund is Equity - Sectoral Fund - Pharma & Health Care.
Sailesh Raj Bhan manages the Nippon India Pharma Fund - Growth Fund.
Nippon India Pharma Fund - Growth current PE ratio is 50.69 and PB ratio is 7.85
The asset allocation of Nippon India Pharma Fund - Growth is Stocks : 96.17%, Debt : 3.84% and Gold : 0%
The minimum SIP amount for Nippon India Pharma Fund - Growth is ₹100.00 and minimum lumpsum is ₹5000.00
The exit load for Nippon India Pharma Fund - Growth is 1% on or before 1 months, Nil after 1 months